In our in vivo and ex vivo experiments, the combination of gemcitabine and CK‐636, a compound identified through molecular docking analysis and SPR analysis as a potential ARPC1B‐targeting agent, demonstrated remarkable synergy in anti‐tumour efficacy. The gene discussed is ARPC1B; the disease is neoplasm.